Recent advances in the identification of genetic and biochemical components of breast cancer predisposition

Current Genomics

Volumn 3, Issue 5, 2002, Pages 389-412

  Sauer, M K ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

BIOCHEMICAL COMPOSITION; BIOLOGICAL TRAIT; BREAST CANCER; CANCER SUSCEPTIBILITY; CELL LINE; CONTROLLED STUDY; DNA MICROARRAY; DNA REPAIR; DNA TRANSCRIPTION; ENVIRONMENTAL FACTOR; GENE AMPLIFICATION; GENE DELETION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS SPECTROMETRY; MOLECULAR CLONING; OVARY CANCER; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TWO HYBRID SYSTEM;

EID: 0036783405     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389202023350264     Document Type: Review

References (210)

1. Inherited genetic predisposition in breast cancer. A population-based perspective
2. Genetic and hormonal risk factors in breast cancer
3. 'Other' breast cancer susceptibility genes: Searching for more holy grail
4. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations
5. TP53 Mutations in Breast Cancer Associated with BRCA1 or BRCA2 Germ- line Mutations: Distinctive Spectrum and'Structural Distribution
6. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat
7. Leaving Kansas ... finding genes in 1997
8. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer
9. Germ line mutations associated with breast cancer susceptibility
10. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus
11. Breast cancer genetics: What we know and what we need
12. Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast Cancer
13. Genetic alterations in breast Cancer
14. Comparative genomic hybridization analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data
15. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast Cancer
16. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease
17. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias
18. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast
19. High rates of loss of heterozygosity on chromosome 19p13 in human breast Cancer
20. Lessons learned from BRCA1 and BRCA2
21. BRCA1 and cell signaling
22. Interactions between BRCA proteins and DNA structure
23. Chromosome stability, DNA recombination and the BRCA2 tumor suppressor
24. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
25. Transcriptional repression of BRCA1 by aberrant cytosine methylation, historic hypoacetylation and chromatin condensation of the BRCA1 promoter
26. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers
27. Overexpression of BRCA2 gene in sporadic breast tumours
28. GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter
29. Regulation of BRCA1 expression by the Rb-E2F pathway
30. The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells
31. Isolation and initial characterization of the BRCA2 promoter
32. Induction of the BRCA2 promoter by nuclear factor-kappa B
33. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach
34. Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter
35. Positive regulation of the BRCA1 promoter
36. Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene
37. Identification and characterization of a transcriptional silencer upstream of the human BRCA2 gene
38. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner
39. Cell cycle control of BRCA2
40. Characterization of BRCA2: Temperature sensitivity of detection and cell-cycle regulated expression
41. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents
42. Ultraviolet irradiation induces BRCA2 protein depletion through a p53- independent and protein synthesis-dependent pathway
43. Regulation of BRCA1 by protein degradation
44. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
45. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination
46. Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity
47. The ring heterodimer brca1-bard1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation
48. BRCA1 is a cell cycle-regulated nuclear phosphoprotein
49. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage
50. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site
51. Casein kinase 2 binds to and phosphorylates BRCA1
52. Identification of a BRCA1-associated kinase with potential biological relevance
53. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells
54. Relationship of p2l5BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells
55. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
56. Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks
57. Substrate specificities and identification of putative substrates of ATM kinase family members
58. Role for ATM in DNA damage-induced phosphorylation of BRCA1
59. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress
60. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage
61. Ataxia Telangiectasia Mutated (ATM) Kinase and ATM and Rad3 Related Kinase Mediate Phosphorylation of Brca1 at Distinct and Overlapping Sites. In vivo assessment using phospho-specific antibodies
62. Involvement of brca1 in s-phase and g(2)-phase checkpoints after ionizing irradiation
63. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
64. The BRCA2 gene product functionally interacts with p53 and RAD51
65. The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase
66. Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1
67. Does this have a familiar RING?
68. Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc
69. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells
70. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
71. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
72. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin- induced apoptosis in ovarian carcinoma cells by proteasome inhibitors
73. Identification of a RING protein that can interact in vivo with the BRCA1 gene product
74. Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1
75. Functional interaction of BRCA1 -associated BARD1 with polyadenylation factor CstF-50
76. The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression
77. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains
78. Genetic analysis of BRCA1 function in a defined tumor cell line
79. BRCA1 physically and functionally interacts with ATF1
80. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases
81. Aberrant subcellular localization of BRCA1 in breast Cancer
82. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b
83. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor
84. Localization of BRCA1 and a splice variant identifies the nuclear localization signal
85. Identification of a functional nuclear export sequence in BRCA1
86. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas
87. Location of BRCA1 in human breast and ovarian cancer cells
88. Association of BRCA1 with Rad51 in mitotic and meiotic cells
89. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype
90. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs
91. Trafficking of nuclear receptors in living cells
92. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells
93. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
94. A novel human rad54 homologue, Rad54B, associates with Rad51
95. Association of BRCA1 with the hRad5O-hMre11-p95 complex and the DNA damage response
96. Independence of R/M/N focus formation and the presence of intact BRCA1
97. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
98. Response: Independence of R/M/N Focus Formation and the Presence of Intact BRCA1
99. From the Cover: Direct DNA binding by Brca1
100. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function
101. VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells
102. BRCA1 is associated with the centrosome during mitosis
103. Centrosome, amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells
104. Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay
105. BRCA1 is associated with a human SWI/SNF-related complex: Linking chromatin remodeling to breast
106. Factors associated with the mammalian RNA polymerase II holoenzyme
107. BRCA1 is a component of the RNA polymerase II holoenzyme
108. BRCA1 protein products. Functional motifs
109. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins
110. From BRCA1 to RAP1: A widespread BRCT module closely associated with DNA repair
111. Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA 1 bind strand breaks and termini of DNA
112. The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature
113. Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1
114. A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling
115. Evidence for a transcriptional activation function of BRCA1 C-terminal region
116. Functional assay for BRCA1: Mutagenesis of the COOH-terminal region reveals critical residues for transcription activation
117. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families
118. Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain
119. BRCA1 can stimulate gene transcription by a unique mechanism
120. Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain
121. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A
122. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription
123. CBP/p300 interact with and function as transcriptional coactivators of BRCA1
124. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p2lWAF1/CiP1
125. BRCA1 regulates p53-dependent gene expression
126. BRCA1 physically associates with p53 and stimulates its transcriptional activity
127. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p2lWAF1/CIP1 promoter
128. BRCA1 signals ARF-dependent stabilization and coactivation of p53
129. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: Evidence for both common and distinct activities of wildtype and mutant forms
130. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells
131. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor
132. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes
133. BRCA1 interacts with components of the histone deacetylase complex
134. BRCA1-associated growth arrest is RB-dependent
135. RB regulates transcription of the p2l/WAF1/CIP1 gene
136. Characterization of a carboxy-terminal BRCA1 interacting protein
137. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression
138. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage
139. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response
140. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor
141. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1
142. BRCA1 inhibition of estrogen receptor signaling in transfected cells
143. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity
144. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells
145. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: Potential interaction between BRCA1 and Sp1
146. Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations
147. Nuclear localization signals of the BRCA2 protein
148. Transcriptional activation functions in BRCA2
149. BRCA2 associates with acetyltransferase activity when bound to P/CAF
150. Internal repeats in the BRCA2 protein sequence
151. The BRC repeats are conserved in mammalian BRCA2 proteins
152. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2
153. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment
154. Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51
155. Expression of BRC repeats in breast cancer cells disrupts the BRCA2- Rad5l complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control
156. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein
157. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo
158. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2
159. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression
160. Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2
161. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals
162. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression
163. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1
164. Gene-expression profiles in hereditary breast Cancer
165. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
166. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
167. Isolation of genes overexpressed in freshly isolated breast cancer specimens
168. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas
169. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast Cancer
170. Rapid analysis of gene expression (RAGE) facilitates universal expression profiling
171. In vivo gene expression profile analysis of human breast cancer progression
172. Molecular portraits of human breast tumours
173. Linking gene expression patterns to therapeutic groups in breast Cancer
174. Gene expression profiling of primary breast carcinomas using arrays of candidate genes
175. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray
176. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate Oncogene
177. Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: A new approach for the molecular analysis of paraffin- tissue
178. Genomewide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis
179. Tissue microarray technology for high-throughput molecular profiling of Cancer
180. Multiple genes at 17q23 undergo amplification and overexpression in breast Cancer
181. Molecular targets for breast cancer therapy and prevention
182. Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations
183. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
184. Mutation and expression analysis of human BUB1 and BUB1B in aneuploid breast cancer cell lines
185. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers
186. Defining biochemical functions for the BRCA1 tumor suppressor protein: Analysis of the BRCA1 binding protein BAP1
187. Fanconi's anemia and malignancies
188. Reassessment of cancer predisposition of Fanconi anemia heterozygotes
189. Identification of Rad51 alteration in patients with bilateral breast Cancer
190. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers
191. Mutations in the RAD54 recombination gene in primary cancers
192. Mutations of a novel human RAD54 homologue, RAD54B, in primary Cancer
193. Alterations of the double-strand break repair gene MRE11 in Cancer
194. Alteration of hMSH2 and DNA polymerase beta genes in breast carcinomas and fibroadenomas
195. Sequence analysis of the mismatch repair gene hMSH6 in the germline of patients with familial and sporadic colorectal Cancer
196. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome
197. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome
198. Germfine BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma
199. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders
200. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies
201. Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival
202. Androgen receptor gene mutation in male breast Cancer
203. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast Cancer
204. AIB1, a steroid receptor coactivator amplified in breast and ovarian Cancer
205. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity
206. The loss of estrogen and progesterone receptor gene expression in human breast Cancer
207. Estrogen receptor variants
208. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions
209. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast Cancer
210. c-myc amplification is an independent prognostic factor in postmenopausal breast Cancer